Publication
Quelantes de metais no tratamento de doenças neurodegenerativas
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 37923 | 1.16 MB | Adobe PDF |
Advisor(s)
Abstract(s)
As doenças neurodegenerativas, como a doença de Alzheimer e a doença de Parkinson, levam à perda progressiva das funções e estruturas neuronais, afetando uma grande parte da população mundial. Na sua origem estarão vários fatores, apontando-se para o desequilíbrio da homeostase dos metais como uma das causas.
Os fármacos utilizados atualmente no tratamento destas doenças têm limitações. Atuam essencialmente no tratamento sintomático e têm vários efeitos secundários. É neste sentido que surge o estudo dos quelantes de metais como potenciais fármacos na terapêutica das doenças neurodegenerativas.
Este trabalho tem como objetivo estudar o potencial dos quelantes de metais no tratamento das doenças neurodegenerativas e conhecer o trabalho de investigação já efetuado nesse âmbito.
Para o desenvolvimento deste trabalho foi realizada uma pesquisa bibliográfica dos estudos feitos dentro deste tema, recorrendo a motores de pesquisa de artigos científicos, livros e páginas WEB.
O interesse pelos quelantes de metais no tratamento das doenças neurodegenerativas é relativamente recente. Os quelantes apresentados neste trabalho obtiveram resultados promissores nos vários ensaios efetuados, mas apresentam algumas limitações farmacocinéticas e efeitos secundários. Serão necessários mais estudos e ensaios clínicos para se perceber a aplicabilidade dos quelantes na terapêutica das doenças neurodegenerativas e contornar as suas limitações.
Neurodegenerative diseases such as Alzheimer's and Parkinson's disease lead to the progressive loss of neuronal functions and structures, affecting a large part of the world's population. Several factors are at the root of these diseases, one of the causes being an imbalance in metal homeostasis. The drugs currently used to treat these diseases have limitations. They essentially act as a symptomatic treatment and have various side effects. It is in this sense that the study of metal chelators as potential drugs in the therapy of neurodegenerative diseases has arisen. The aim of this work is to study the potential of metal chelators in the treatment of neurodegenerative diseases and to find out what research has already been done in this area. In order to carry out this work, bibliographical research of the studies on this subject was carried out, using search engines to search for scientific articles, books and websites. The interest in metal chelators in the treatment of neurogenerative diseases is relatively recent. The chelators presented in this work have obtained promising results in the various trials carried out but have some pharmacokinetic limitations and side effects. More studies and clinical trials will be needed to understand the applicability of chelators in the treatment of neurodegenerative diseases and to overcome their limitations.
Neurodegenerative diseases such as Alzheimer's and Parkinson's disease lead to the progressive loss of neuronal functions and structures, affecting a large part of the world's population. Several factors are at the root of these diseases, one of the causes being an imbalance in metal homeostasis. The drugs currently used to treat these diseases have limitations. They essentially act as a symptomatic treatment and have various side effects. It is in this sense that the study of metal chelators as potential drugs in the therapy of neurodegenerative diseases has arisen. The aim of this work is to study the potential of metal chelators in the treatment of neurodegenerative diseases and to find out what research has already been done in this area. In order to carry out this work, bibliographical research of the studies on this subject was carried out, using search engines to search for scientific articles, books and websites. The interest in metal chelators in the treatment of neurogenerative diseases is relatively recent. The chelators presented in this work have obtained promising results in the various trials carried out but have some pharmacokinetic limitations and side effects. More studies and clinical trials will be needed to understand the applicability of chelators in the treatment of neurodegenerative diseases and to overcome their limitations.
Description
Keywords
Doenças neurodegenerativas Doença de Alzheimer Doença de Parkinson Metais Quelante β-amiloide Tau Ferro Cobre Zinco Demência Neurodegenerative disease Parkinson disease Alzheimer disease Metal Chelating agent β-amyloid Iron Copper Zinc Dementia